Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has selected Crown CRO, based in Finland, to manage its Phase III trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for the Phase III trial will enroll 290 patients in 30 clinical sites across Europe. William Stilley, chief executive officer of Adial Pharmaceuticals, said, “We are excited to begin our Phase III trial of AD04 in the first half of 2019, and look forward to partnerin...